Immunologik

Hamburg, Germany· Est. 2003

The ImmunoLogik GmbH develops innovative active substances for the efficient and essential treatment of HIV and SARS-CoV-2 infected people

Private Company

Funding information not available

About

The ImmunoLogik GmbH develops innovative active substances for the efficient and essential treatment of HIV and SARS-CoV-2 infected people

ImmunologyInfectious Disease

More companies in Immunotherapy / Immuno-Oncology →More companies in Germany →